What is new in amyloidosis treatment? Part 1: Light chains
Article Sidebar
Main Article Content
Abstract
AL amyloidosis is a disease caused by the deposit in different organs and tissues of protein fibrils formed by light chains synthetized by pathological clonal plasma cells. Its treatment is currently aimed at eradicating this plasma cell clone and it has been historically extrapolated from available and validated treatments for other blood dyscrasias.
In 2020, the Amyloidosis Study Group prepared different clinical practice guidelines for the treatment of AL amyloidosis.
Since then, clinical trials have been published that confirm and strengthen the knowledge available up to now, and new lines of research are being developed that stimulate study in the area. In this review, an update of the existing guidelines regarding the treatment of AL amyloidosis is made.
As relevant evidence, in the last year, results of clinical trials have been made available that support the use of regimens based on daratumumab (an anti-CD38+ monoclonal antibody) for patients with newly diagnosed AL amyloidosis as first line therpya. In addition, for the treatment of refractory or relapsed AL amyloidosis, where the availability of supporting literature is scant and extrapolated from the treatment of multiple myeloma, there is currently quality evidence to recommend the use of ixazomib, an oral reversible proteasome inhibitor, only available in Argentina since 2020.
Finally, some research lines exploring the efficacy of other monoclonal antibodies and therapeutic experiments based on the use of CAR-T cells are mentioned.
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
References
Brulc EB, Carretero M, Aguirre MA, et al. Recomendaciones para el tratamiento de la amiloidosis AL. Medicina (B Aires). 2022;82(4):591-604.
Hospital Italiano de Buenos Aires (HIBA). Servicio de Clínica Médica. Área de Investigación de Medicina Interna. Grupo de Estudio de Amiloidosis (GEA). Guía de práctica clínica de diagnóstico de pacientes con amiloidosis sistémica. Trovare Repositorio Institucional [Preprint]. 2022 [citado 2023 ene 11]: [431 p.]. Disponible en: https://trovare.hospitalitaliano.org.ar/greenstone/collect/revistas/index/assoc/D1179.dir/preprint-gea-2021.pdf.
Kastritis E, Palladini G, Minnema MC, et al. Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med. 2021;385(1):46-58. https://doi.org/10.1056/NEJMoa2028631. DOI: https://doi.org/10.1056/NEJMoa2028631
Vaxman I, Dispenzieri A. The role of autologous stem cell transplantation in amyloidosis. Oncology (Williston Park). 2021;35(8):471-478. https://doi.org/10.46883/ONC.2021.3508.0471. DOI: https://doi.org/10.46883/ONC.2021.3508.0471
Sanchorawala V, Sun F, Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood. 2015;126(20):2345-2347. https://doi.org/10.1182/blood-2015-08-662726. DOI: https://doi.org/10.1182/blood-2015-08-662726
Dispenzieri A, Kastritis E, Wechalekar AD, et al. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia. 2022;36(1):225-235. https://doi.org/10.1038/s41375-021-01317-y. DOI: https://doi.org/10.1038/s41375-021-01317-y
Wechalekar AD, Cibeira MT, Gibbs SD, et al. Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group. Amyloid. 2023;30(1):3-17. https://doi.org/10.1080/13506129.2022.2093635. DOI: https://doi.org/10.1080/13506129.2022.2093635
Premkumar VJ, Lentzsch S, Pan Set al. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021;11(1):10. https://doi.org/10.1038/s41408-020-00397-w. DOI: https://doi.org/10.1038/s41408-020-00397-w
Parker TL, Rosenthal A, Sanchorawala V, et al. Phase II study of Isatuximab (SAR650984) (NSC-795145) for patients with previously treated AL amyloidosis (SWOG S1702; NCT#03499808). Blood. 2020;136(Suppl 1):20-21. https://doi.org/10.1182/blood-2020-143180. DOI: https://doi.org/10.1182/blood-2020-143180
Gertz MA, Tipuraneni R, Kinney G. Birtamimab in patients with mayo stage IV AL amyloidosis: rationale for confirmatory affirm-AL phase 3 study design. Blood 2021;138(Suppl 1):2754. https://doi.org/10.1182/blood-2021-146076. DOI: https://doi.org/10.1182/blood-2021-146076
Edwards CV, Rao N, Bhutani D, et al. Phase 1a/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis. Blood. 2021;138(25):2632-2641. https://doi.org/10.1182/blood.2020009039 DOI: https://doi.org/10.1182/blood.2020009039